News
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate
Puma Biotechnology Releases Updated Corporate Presentation
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, presented at
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced they
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced they
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced an exclusive four-year
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
DGAP-News: MorphoSys präsentiert auf der 40. jährlichen J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys präsentiert auf der 40. jährlichen J.P. Morgan Healthcare Conference
DGAP-News: MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
argenx Highlights Strategic Priorities for 2022
Regulatory News:
argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its strategic
DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-News: MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-News: MorphoSys gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-News: MorphoSys gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG gibt vorläufigen Monjuvi-Umsatz für 2021 bekannt und veröffentlicht Finanzprognose für 2022
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
DGAP-Adhoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Transgene Announces Financial Calendar for 2022
Regulatory News:
TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2022:
March 16, 2022: 2021 Fiscal Year Results
May 10, 2022: First Quarter 2022 Financial Results
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that Sanofi will be transitioning its rights and obligations related to SAR445136, a zinc finger nuclease
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for
ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual